Adaptive Biotechnologies Corp
ADPT
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.99B
Close$
$3.64
85.1% downside
Current Fair Value
85.1% downsideOvervalued by 85.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.99 Billion |
|---|---|
| Enterprise Value | $4.28 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.39 |
| Beta | 2.07 |
| Outstanding Shares | 157,700,126 |
Return
| Return on Equity | -44.68% |
|---|---|
| Return on Assets | -9.97% |
| Return on Invested Capital | -6.60% |
Valuation & Multiples
| P/E Ratio | -61.19 |
|---|---|
| PEG | -110.58 |
| Price to Sales | 24.46 |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 13.9 |
| Enterprise Value to EBIT | -117.46 |
| Enterprise Value to Net Income | -68 |
| Total Debt to Enterprise | 0.11 |
| Debt to Equity | 3.24 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 4, 2026
EPS Estimate
$-0.13
Average shareholder expectationRevenue Estimate
$65.44 M
Average shareholder expectationNext Earnings Call
Expected Date
November 4, 2026
EPS Estimate
$-0.10
Average shareholder expectationRevenue Estimate
$71.65 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 15.11% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 19.56%▼ 79.61% |
|---|---|
| Total Invested | $652.28M▼ 69.05% |
| Investors Holding | 125▼ 174.00% |
ESG Score
No data
About Adaptive Biotechnologies Corp
CEO: Chad Robins Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Adaptive Biotechnologies believes the adap...